Arcus Biosciences, INC. (RCUS) — 8-K Filings

8-K Filings (18)

• Arcus Biosciences Files 8-K — Apr 20, 2026 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on April 20, 2026, reporting other events. The filing does not contain specific financial figures or material events beyond
• Arcus Biosciences Enters Material Definitive Agreement — Dec 18, 2025 Risk: medium
  On December 18, 2025, Arcus Biosciences, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered i
• 8-K Filing — Dec 12, 2025
• 8-K Filing — Nov 3, 2025
• Gilead to Acquire Arcus Biosciences for $12.8B — Oct 14, 2025 Risk: medium
  Arcus Biosciences, Inc. announced on October 12, 2025, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. The transaction i
• Arcus Biosciences Files 8-K — Oct 6, 2025 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on October 6, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the event i
• Arcus Biosciences Files 8-K with Shareholder Vote and Financials — Jun 12, 2025 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders and other events. The filing includes financ
• Gilead to Acquire Arcus Biosciences for $12.8B — Jun 2, 2025 Risk: medium
  Arcus Biosciences, Inc. announced on June 1, 2025, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $12
• Arcus Biosciences Files 8-K: Other Events & Exhibits — Feb 19, 2025 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on February 19, 2025, reporting other events and financial statements/exhibits. The filing date is February 19, 2025, with
• Arcus Biosciences Files 8-K — Feb 18, 2025 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on February 18, 2025, reporting on results of operations and other events as of February 15, 2025. The filing does not cont
• Arcus Biosciences CEO Departs, New CEO Appointed — Feb 6, 2025 Risk: medium
  Arcus Biosciences, Inc. announced on February 6, 2025, the departure of Dr. Terry Rosen from his role as Chief Executive Officer and a member of the Board of Di
• Arcus Biosciences Elects New Directors, Adjusts Executive Pay — Jan 21, 2025 Risk: medium
  Arcus Biosciences, Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elec
• Gilead to Acquire Arcus Biosciences for $12.8B — Oct 24, 2024 Risk: medium
  Arcus Biosciences, Inc. announced on October 24, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately
• Arcus Biosciences Enters New Credit Agreement — Aug 27, 2024 Risk: medium
  On August 27, 2024, Arcus Biosciences, Inc. entered into a material definitive agreement, specifically a credit agreement with certain lenders. This agreement c
• Arcus Biosciences Files 8-K — Jun 6, 2024 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on June 6, 2024, to report on the submission of matters to a vote of security holders, other events, and financial statemen
• Gilead to Acquire Arcus Biosciences for $12.8B — Jun 3, 2024 Risk: medium
  Arcus Biosciences, Inc. announced on June 2, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $12
• Gilead to Acquire Arcus Biosciences for $12.8 Billion — May 23, 2024 Risk: medium
  Arcus Biosciences, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $12
• Arcus Biosciences Reports Material Agreement, Equity Sales, Officer Comp Changes — Jan 30, 2024
  Arcus Biosciences, Inc. filed an 8-K on January 30, 2024, reporting events from January 29, 2024, including entering into a material definitive agreement, unreg

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX